Thor Medical ASA 2023 AR2
The report outlines Thor Medical's strategic repositioning in 2023 following the acquisition of Thor Medical AS by Nordic Nanovector ASA, which was subsequently renamed Thor Medical ASA. The company focused on developing its proprietary technology for manufacturing alpha-emitting radionuclides for cancer therapy, independent of nuclear reactors. Key achievements included signing three letters of intent with radiopharmaceutical companies and executing the investment decision to build a pilot plant at Heroya Industrial Park. Financially, the company remained in a pre-commercial phase with no revenues, reporting a net loss of NOK 15.7 million for the parent company and preserving a cash position of NOK 41.8 million.
Company: Thor Medical ASA
Sector: Health Care
Country: Norway
Year: 2023
Type: AR2
Pages: 92
Thor Medical ASA
Annual Report
The report outlines Thor Medical's strategic repositioning in 2023 following the acquisition of Thor Medical AS by Nordic Nanovector ASA, which was subsequently renamed Thor Medical ASA. The company focused on developing its proprietary technology for manufacturing alpha-emitting radionuclides for cancer therapy, independent of nuclear reactors. Key achievements included signing three letters of intent with radiopharmaceutical companies and executing the investment decision to build a pilot plant at Heroya Industrial Park. Financially, the company remained in a pre-commercial phase with no revenues, reporting a net loss of NOK 15.7 million for the parent company and preserving a cash position of NOK 41.8 million.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Employees